RSS | Login | Register

RETROVIR TABLETS

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare RETROVIR TABLETS to:

Generic Name for RETROVIR TABLETS

Zidovudine 300mg.

Legal Classification:

Pharmacological Class for RETROVIR TABLETS

Nucleoside analogue (reverse transcriptase inhibitor).

Manufacturer of RETROVIR TABLETS

GlaxoSmithKline Pharmaceuticals

Indications for RETROVIR TABLETS

HIV infection. Prevention of maternal-fetal HIV transmission.

Adult dose for RETROVIR TABLETS

≥18yrs: 600mg daily in divided doses. End-stage renal disease on dialysis: 100mg every 6–8 hours. Vertical transmission, severe anemia and/or neutropenia: see literature.

Children's dosing for RETROVIR TABLETS

<6 weeks and/or for vertical transmission: see literature. 6 weeks to <18yrs: (4 to <9kg): 24mg/kg/day (12mg/kg twice daily or 8mg/kg 3 times daily); (≥9 to <30kg): 18mg/kg/day (9mg/kg twice daily or 6mg/kg 3 times daily); (≥30kg): 600mg/day (300mg twice daily or 200mg 3 times daily). Alternative dosing based on BSA: 480mg/m²/day (240mg/m² twice daily or 160mg/m² 3 times daily).

Also:

RETROVIR CAPSULES

RETROVIR IV

RETROVIR SYRUP

Precautions for RETROVIR TABLETS

Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Monitor for hematologic toxicity; reduce dose or suspend if significant anemia and/or granulocytopenia occurs; transfuse if necessary. Renal or hepatic dysfunction: consider reducing dose. Bone marrow suppression. Risk of liver disease. Women, obesity, prolonged nucleoside exposure, or advanced HIV disease: increased risk of toxicity. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for RETROVIR TABLETS

Avoid stavudine, doxorubicin, ribavirin, other nucleoside analogues, other forms of zidovudine. Caution with other cytotoxic or myelosuppressive drugs (eg, ganciclovir, interferon-alpha, ribavirin). Fluconazole, atovaquone, lamivudine, probenecid, valproic acid, methadone increase zidovudine levels. Monitor phenytoin. May be antagonized by rifampin, ritonavir, nelfinavir. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.

Adverse Reactions for RETROVIR TABLETS

Anemia, neutropenia, headache, malaise, GI disturbances, insomnia, pain, myopathy, neuropathy, myositis, thrombocytopenia, lactic acidosis, steatosis, hepatomegaly, fat redistribution, immune reconstitution syndrome, pancreatitis, others. Children: also fever, cough.

How is RETROVIR TABLETS supplied?

Tabs—60
Caps—100
Syrup—240mL
IV (20mL/vial)—10

Related Disease:

HIV~antivirals

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

FDA update on H1N1 vaccine safety monitoring

January 19, 2010

The Commissioner of Food and Drugs has issued a letter to update healthcare professionals on the FDA/CDC experience with the H1N1 vaccination program and to provide some detail on the current vaccine safety monitoring program.